Genentech, a unit of Roche Holding AG (RHHBY), on Monday reported positive top-line results from its Phase III ALLEGORY study evaluating Gazyva in adults with systemic lupus erythematosus (SLE) receiving standard therapy.
The study met its primary endpoint showing a higher proportion of patients achieving at least four-point improvement in the SLE Responder Index 4 (SRI-4) at 52 weeks compared with standard therapy alone.
SRI is a tool used to assess changes in disease severity, symptoms, and physical condition to determine treatment effectiveness in controlling disease activity.
No new safety signals were identified, and safety profile was in line with the established clinical experience for Gazyva.
Gazyva is also being investigated in children and adolescents with lupus nephritis, as well as adults with membranous nephropathy.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.